MTOR and nonpapillary renal cell carcinoma: For example, vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) inhibitors, and RAF kinase have been used to treat ccRCC (7), but these drugs often encounter the problem of drug resistance in clinical application.